Rafarma Pharmaceuticals has made a significant investment in a 270,000-square-foot state-of-the-art production facility in the economic development zone in Terbuny, Lipetsk Region, south of Moscow. This sprawling, multi-profile pharmaceutical plant has the capability and space to produce all types and forms of medical drugs of various pharmacological groups.
The facility was designed to accommodate a fair share of the burgeoning Russian pharmaceutical market, which is growing in tremendous leaps and bounds following an aggressive development campaign launched by the Russian government in 2010.
Upon full production, which is expected to commence later this year, Rafarma anticipates being one of the leaders in the nation's "big pharma."
The QualityStocks Production team recently compiled an informative video on Rafarma, specifically highlighting the company's facility and support the company has received from the Ministry of Industry and Trade of the Russian Federation, The Russian Ministry of Health, and The Administration of Lipetsk.
"It's one of the most ambitious projects in Russian industry in recent years … this facility permits us to introduce into our manufacturing practice modern scientific developments, and it permits us to improve the technology of our production constantly," Julia Andryshokova , member of ZAO Rafarma's board of directors, says in the video. "Our strategy does permit us to see ourselves at the top of leaders of Russia's pharmaceutical market."
To view the entire production, visit qualitystocks.net/videos.php
For more information on Rafarma, visit rafarma.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.